[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609996":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":31,"locations":37,"responsibleParty":141,"collaborators":21,"id":143,"slug":21,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":144,"sex":150,"minAge":151,"maxAge":21,"enrollmentInfo":152,"targetDuration":21,"studyType":155,"phases":156,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":69,"whyStopped":21,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"Alexion Pharmaceuticals, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Corticosteroid Tapering Schedule","EXPERIMENTAL","During the tapering period, participant will follow an Oral Corticosteroid tapering schedule until OCS tapering is complete",[13,14,15],"Procedure: Oral Corticosteroid Tapering Schedule","Drug: Ravulizumab","Drug: Prednisone\u002FPrednisolone",[17,22,27],{"type":18,"name":9,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","During the tapering period, participant will follow an Oral Corticosteroid tapering schedule as applicable to the participant. The oral corticosteroid (prednisone\u002Fprednisolone) is provided as per standard medical care.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","Ravulizumab","Patients being treated with intravenous ravulizumab as part of their standard medical care.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":21},"Prednisone\u002FPrednisolone","Participants will continue with or be switched to prednisone\u002Fprednisolone as per standard medical care.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},"Alexion Pharmaceuticals, Inc. (Sponsor)","CONTACT","1-855-752-2356","clinicaltrials@alexion.com",[38,51,59,68,78,87,96,105,113,121,130,133],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":21},"Research Site","NOT_YET_RECRUITING","Chicago","Illinois","60637","United States",{"type":46,"coordinates":47},"Point",[48,49],-87.65005,41.85003,{"lat":49,"lon":48},{"facility":39,"status":40,"city":52,"state":42,"zip":53,"country":44,"cosmosGeoPoint":54,"geoPoint":58,"contacts":21},"Schaumburg","60173",{"type":46,"coordinates":55},[56,57],-88.08341,42.03336,{"lat":57,"lon":56},{"facility":39,"status":40,"city":60,"state":61,"zip":62,"country":44,"cosmosGeoPoint":63,"geoPoint":67,"contacts":21},"Neptune City","New Jersey","07753",{"type":46,"coordinates":64},[65,66],-74.02792,40.20011,{"lat":66,"lon":65},{"facility":39,"status":69,"city":70,"state":71,"zip":72,"country":44,"cosmosGeoPoint":73,"geoPoint":77,"contacts":21},"RECRUITING","Raleigh","North Carolina","27607",{"type":46,"coordinates":74},[75,76],-78.63861,35.7721,{"lat":76,"lon":75},{"facility":39,"status":40,"city":79,"state":80,"zip":81,"country":44,"cosmosGeoPoint":82,"geoPoint":86,"contacts":21},"Knoxville","Tennessee","37920",{"type":46,"coordinates":83},[84,85],-83.92074,35.96064,{"lat":85,"lon":84},{"facility":39,"status":40,"city":88,"state":21,"zip":89,"country":90,"cosmosGeoPoint":91,"geoPoint":95,"contacts":21},"Bochum","44789","Germany",{"type":46,"coordinates":92},[93,94],7.21648,51.48165,{"lat":94,"lon":93},{"facility":39,"status":40,"city":97,"state":21,"zip":98,"country":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":21},"Milan","20122","Italy",{"type":46,"coordinates":101},[102,103],12.59836,42.78235,{"lat":103,"lon":102},{"facility":39,"status":40,"city":106,"state":21,"zip":107,"country":99,"cosmosGeoPoint":108,"geoPoint":112,"contacts":21},"Naples","80131",{"type":46,"coordinates":109},[110,111],14.26811,40.85216,{"lat":111,"lon":110},{"facility":39,"status":40,"city":114,"state":21,"zip":115,"country":99,"cosmosGeoPoint":116,"geoPoint":120,"contacts":21},"Rome","00189",{"type":46,"coordinates":117},[118,119],12.51133,41.89193,{"lat":119,"lon":118},{"facility":39,"status":40,"city":122,"state":21,"zip":123,"country":124,"cosmosGeoPoint":125,"geoPoint":129,"contacts":21},"Ibaraki","305-8576","Japan",{"type":46,"coordinates":126},[127,128],135.56828,34.81641,{"lat":128,"lon":127},{"facility":39,"status":40,"city":131,"state":21,"zip":132,"country":124,"cosmosGeoPoint":21,"geoPoint":21,"contacts":21},"Kitakyushu-shi","807-8555",{"facility":39,"status":40,"city":134,"state":21,"zip":135,"country":124,"cosmosGeoPoint":136,"geoPoint":140,"contacts":21},"Kumamoto","860-8556",{"type":46,"coordinates":137},[138,139],130.69181,32.80589,{"lat":139,"lon":138},{"type":142,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100609996",false,"NCT07221838","A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","OCTAGON: A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients With Generalized Myasthenia Gravis Treated With Ravulizumab","OCTAGON","Inclusion Criteria:\n\n* Aged greater than 18 years and male or female\n* Clinical diagnosis of gMG\n* Receiving ravulizumab treatment prior to enrollment\n* Receipt of OCS therapy equivalent to a daily dose ≥ 7.5 mg of prednisone\u002Fprednisolone for ≥ 4 continuous weeks directly preceding enrollment\n* A participant of childbearing potential must have a negative highly sensitive pregnancy test (serum or urine, as required by local regulations) taken at Screening before OCS tapering begins.\n* Willing to sign informed consent\n\nExclusion Criteria:\n\n* Concurrent participation in an interventional clinical trial.\n* History of chronic hypoadrenalism (ie, Addison's disease).\n* Use of concomitant OCS for comorbid conditions other than gMG\n* Receipt of a biologic for gMG (e.g., efgartigimod, rozanolixizumab, inebilizumab, rituximab, intravenous immunoglobulin) within 5 half-lives of enrollment\n* Pregnant, breastfeeding, or intending to conceive during the course of the study","ALL","18 Years",{"count":153,"type":154},75,"ESTIMATED","INTERVENTIONAL",[157],"PHASE4","This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.",[160,161],"Generalized Myasthenia Gravis","gMG",[163,161,164,165,166,167,168,169,170,171],"Generalized myasthenia gravis","Glucocorticoid toxicity","Complement C5 inhibitor","Prednisone reduction","Cortisol monitoring","ravulizumab","corticosteroids","adrenal insufficiency","steroid sparing","2026-04-06",{"date":174,"type":175},"2026-04-09","ACTUAL",{"date":177,"type":175},"2026-03-04",{"date":179,"type":154},"2027-08-27",{"name":5,"class":6},12]